Table 1.
Characteristics of the 21 acromegaly patients at the time of baseline prepegvisomant testing
| Male/Female | 13/8 |
| Age years median (range) | 48 (19-62) |
| Hypopituitarism | |
| Hypogonadism | |
| Males | |
| Testosterone treateda | 7 (33) |
| Untreated | 1 (5) |
| Females | |
| Postmenopauseb | 3 (14) |
| Secondary amenorrheab | 3 (14) |
| Hypothyroidism | 2 (9.5) |
| Comorbidities | |
| Hypertension | 12 (57) |
| Diabetes mellitus | 6 (29)d |
| Osteoarthritis | 6 (29) |
| Hyperlipidemia | 5 (23) |
| Sleep apnea | 5 (23) |
| Carpal tunnel syndrome | 2 (9.5) |
| Prior therapy | |
| Transsphenoidal surgery | 20 (95) |
| Radiotherapy | 8 (38) |
| Somatostatin analog | 18 (86) |
| Cabergoline | 13 (62) |
| Bromocriptine | 5 (24) |
| Pergolide | 1 (5) |
| Years from surgeryc | 3.05 (0.75-13) |
| Years from radiotherapyc | 1.15 (0.4-10.5) |
Data are presented as n (%) unless stated otherwise.
a Testosterone level within normal range on testosterone therapy for duration of study.
b Not on hormone replacement therapy for duration of study.
c Median and range of years from surgery or radiotherapy to the baseline testing in this study.
d Four treated with medical therapy, 2 with insulin.